Details for Patent: 11,058,667
✉ Email this page to a colleague
Which drugs does patent 11,058,667 protect, and when does it expire?
Patent 11,058,667 protects ENTRESTO and is included in one NDA.
This patent has sixteen patent family members in fourteen countries.
Summary for Patent: 11,058,667
| Title: | Sacubitril-valsartan dosage regimen for treating heart failure |
| Abstract: | The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient. |
| Inventor(s): | Rizkala; Adel Remond (East Brunswick, NJ), Shi; Victor Chengwei (Mendham, NJ), Chen; Fabian (Englewood Cliffs, NJ) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 15/572,399 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 11,058,667
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE | ⤷ Sign Up | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE | ⤷ Sign Up | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,058,667
| PCT Information | |||
| PCT Filed | May 09, 2016 | PCT Application Number: | PCT/IB2016/052633 |
| PCT Publication Date: | November 17, 2016 | PCT Publication Number: | WO2016/181284 |
International Family Members for US Patent 11,058,667
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Cyprus | 1126036 | ⤷ Sign Up | |||
| Denmark | 3294283 | ⤷ Sign Up | |||
| European Patent Office | 3294283 | ⤷ Sign Up | |||
| European Patent Office | 4212152 | ⤷ Sign Up | |||
| Spain | 2945866 | ⤷ Sign Up | |||
| Finland | 3294283 | ⤷ Sign Up | |||
| Croatia | P20230480 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
